Neutrophil gelatinase-associated lipocalin levels are U-shaped in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study—Impact for mortality

Rainer P. Woitas1*, Hubert Scharnagl2, Marcus E. Kleber3, Graciela E. Delgado3, Tanja B. Grammer3, Martin Pichler4, Bernhard K. Krämer3, Winfried März2,3,5, Tatjana Stojakovic2

1 The Department of Internal Medicine I–Division of Nephrology, University of Bonn, Bonn, Germany, 2 Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria, 3 Medical Clinic V (Nephrology, Hypertensiology, Endocrinology, Diabetology, Rheumatology), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany, 4 Department of Internal Medicine, Division of Clinical Oncology, Medical University of Graz, Graz, Austria, 5 Synlab Academy, Synlab Services GmbH, Mannheim, Germany

* woitas@uni-bonn.de

Abstract

Introduction

Neutrophil gelatinase–associated lipocalin (NGAL) is a glycoprotein released by damaged renal tubular cells and mature neutrophils. It is elevated in kidney injury, but also in patients with coronary artery disease (CAD) and myocardial infarction. We investigated the prognostic value of NGAL for total and cardiovascular mortality in patients undergoing coronary angiography without history of renal insufficiency at inclusion into the study.

Participants

The LURIC study is an ongoing prospective cohort study of patients referred for coronary angiography and is designed to evaluate determinants of cardiovascular health.

Results

NGAL was determined in plasma of 2997 persons (mean age: 62.7 years; 69.7% men) with a follow up for 10 years. 2358 patients suffered from CAD and 638 did not—these patients served as controls. Stable CAD was found in 1408 and unstable CAD in 950 patients. Death rate from cardiovascular events and all causes was highest in patients within the 4th quartile of NGAL (>56 ng/ml, p<0.001 vs third quartile), even after adjustment for age and gender. According to multivariable-adjusted Cox analysis adjusting for well-known cardiovascular risk factors, as well as lipid lowering therapy, angiographic CAD, and C-reactive protein we found patients in the highest NGAL quartile being at increased risk for cardiovascular (hazard ratio (HR) 1.33, 95%CI 1.05–1.67, p = 0.016) and all cause mortality (HR 1.29 95%CI 1.07–1.55, p = 0.007) compared to those in the third quartile. The lowest risk was seen in the third quartile of NGAL (41–56 ng/ml) suggesting a U-shaped relationship between
NGAL and mortality. Further adjustment for creatinine abrogated the predictive effect of NGAL. However, the 3rd and 4th quartiles of NGAL were significantly associated with higher neutrophil counts, which were associated with CAD, non-ST elevation and ST-elevation myocardial infarction (p<0.05).

Conclusions
Plasma NGAL concentrations are mainly derived from neutrophils and do not predict mortality independent of renal function.

Introduction
Neutrophil gelatinase-associated lipocalin (NGAL) is a 25 kDa glycoprotein of the lipocalin family, which consists of a single disulfide bridged polypeptide chain of 178 amino acid residues that is stored in granules of neutrophil leukocytes [1]. Although the major source of plasma NGAL are neutrophils it is also found in monocytes, hepatocytes, endothelial and smooth muscle cells, renal tubular cells [2, 3]. It has been linked to acute tubular kidney injury, chronic kidney disease progression, neutrophil activation and atherogenesis [4].

The most important biological functions of NGAL are the transport of small, hydrophobic ligands thus mediating inflammatory response and inhibition of bacterial growth [5, 6]. Inflammatory activity is mediated through binding to chemotactic peptides, leukotrienes, and platelet-activating factor [7, 8]. NGAL is upregulated in endothelial dysfunction and inflammatory vascular damage [9–11]. Elevated NGAL expression was also noted in atherosclerotic plaques and was associated with infiltrating inflammatory cells, thrombus formation, plaque hemorrhage, and central necrosis [3, 10, 12]. Furthermore, aldosterone induces metalloproteinase-9 (MMP-9) and MMP-9/NGAL protein complex in neutrophils [13]. Formation of this complex with MMP-9, which is an important mediator of plaque instability and vascular remodeling, may be involved in plaque rupture.

Circulating NGAL may indirectly contribute to inflammatory processes, atherogenesis and subsequent progression of cardiovascular diseases [7, 9, 14]. NGAL was an independent predictor of major adverse cardiovascular events and mortality [15–17]. Elevated NGAL levels were found in the presence of CAD and correlated with the severity of cardiovascular disease (CVD) [11]. Elevated NGAL was also found in patients with acute myocardial infarction (MI), being a strong outcome predictor in patients with ST-elevation MI (STEMI) [18]. Recently a strong association of NGAL with inflammation and with 10-year outcomes in the general population was noted. Furthermore, NGAL improved cardiovascular risk stratification when added to the Framingham risk score [19]. Therefore, we investigated the predictive role of NGAL for total and cardiovascular mortality in patients undergoing coronary angiography in the LURIC cohort [20].

Material and methods
Study design and participants
The Ludwigshafen Risk and Cardiovascular Health (LURIC) study is an ongoing prospective cohort study of patients referred for coronary angiography and is designed to evaluate the effects of biomarkers on the cardiovascular system. Study design and baseline examinations have been described previously in detail. [20]. In total, 3,316 subjects (2,309 men and 1,007 women) aged 18 to 95 years were recruited from July 1997 to January 2000 at the Heart Center
Ludwigshafen in Germany. Patients were included into the study if a coronary angiogram was performed and clinical conditions were stable with the exception of an acute coronary syndrome (ACS). In 2997 patients plasma NGAL measurements were available. No study participants were lost to follow-up. We did not record how many subjects were suitable to inclusion, but who did not give written informed consent.

Patients, who suffered from any other diseases than ACS, e.g., chronic renal failure, severe rheumatic arthritis, persistent incapacitation or a history of malignancy were excluded.

Written informed consent was obtained from each participant. The study complies with the Declaration of Helsinki and was approved by the institutional review board at the Medical Association of Rheinland-Pfalz. Detailed descriptions of the LURIC baseline examination are provided elsewhere [20].

Brachial artery pressure values, the extent of heart failure (HF) was assessed as described in detail previously [21]. The diagnosis of an ACS was established when patients presented within 15 days of the beginning of disorders of unstable angina pectoris or acute MI, comprising non-ST-elevation MI (troponin T > 0.1 μg/L) and ST-elevation MI. Dyslipidaemia was defined as HDL cholesterol <1 mmol/L (40 mg/dL), and/or LDL cholesterol > 4.1 mmol/L (160 mg/dL), and/or triglycerides (TG) >2.4 mmol/L (200 mg/dL) [22]. Diagnosis of diabetes was established according to the definition of the American Diabetes Association [23]. Antihypertensive treatment [ACE-inhibitors (ACEi), Ang-II type-1 receptor blockers (ARBs), beta-blockers, calcium channel blockers, and diuretics] as well as the current smoking status were recorded accordingly.

The second follow-up of the LURIC cohort for mortality is the basis of the underlying analysis; the censoring date was June 30, 2009. During the follow-up no patients were lost. Causes of death were extracted from death certificates. Death certificates were missing for 18 deceased participants of the 2997 individuals who were included in the analysis for total mortality but excluded from the analysis of cardiovascular mortality.

Laboratory parameters

Blood samples were drawn in the morning before cardiac catheterization, after subjects had fasted. Serum and EDTA plasma aliquots were shock frozen and stored at −80°C for later use. Leukocytes were prepared using a whole blood lyse no-wash method, according to manufacturer recommendations (BectonDickinson). Preparations were analyzed on a four-color flow cytometer (FACSCalibur, BectoneDickinson) by standard procedures [24].

Phlebotomy for venous blood samples was done in the morning before coronary angiography with the participants in supine position for 5–10 min before phlebotomy. Routine laboratory parameters were immediately measured whereas remaining blood samples were snap frozen for further determination and stored at -80°C until analysis. The standard laboratory methods have been described in detail elsewhere [20].

IDMS-traceable creatinine was determined by liquid chromatography tandem mass spectrometry (LC-MS/MS) [25]. Within-day and between-day coefficients of variation (CVs) were 4.5% (59 μmol/L) and 2.9% (477 μmol/L), and 9.6% (53 μmol/L) and 7.5% (504 μmol/L), respectively. High-sensitive (hs) C-reactive protein (CRP) and cystatin C were measured by immunonephelometry (N-High-Sensitive CRP; N-Latex cystatin C, Dade Behring, Marburg, Germany) using a Behring nephelometer II. The intra-assay and inter-assay CVs were 2.2% and 2.5%, respectively as described in detail previously [21]. The CKD Epidemiology Collaboration (CKD-EPI) equation (eGFR_{CKD-EPI}) was used to calculate estimated glomerular filtration rate (eGFR) [26]. Neutrophil gelatinase-associated lipocalin (NGAL) was measured in EDTA-plasma using a particle-enhanced turbidimetric immunoassay (BioPorto Diagnostics,
Gentofte, Denmark) on an Olympus AU640 analyzer (Olympus Diagnostika, Hamburg, Germany). The day-to-day coefficient of variation was <3%.

Statistical analysis

Continuous parameters following non-normal distributions underwent natural logarithmic transformation. Baseline characteristics are given as percentages for categorical data, and depending on their distribution, continuous data are presented as mean±SD (normal distribution) or as geometric means with 95% confidence intervals (95%CI) (skewed distribution). Comparisons between groups were performed by analysis of variance for continuous parameters and by Pearson’s chi-square test for categorical variables. We studied the effects of gender, age, CAD, and cardiovascular risk factors, on NGAL using ANOVA models in which we included those factors not under examination as co-variables; NGAL values were logarithmically transformed prior to statistical analysis. Kaplan-Meier survival function with the log-rank test for equality was used to evaluate the predictive ability of quartiles of NGAL or neutrophils with overall and CVD mortality.

Time-to-event analyses were performed using multivariate Cox proportional-hazards regression. Established cardiovascular risk factors were determined a priori as co-variables for multivariate adjustments. Besides the crude and unadjusted model, model 2 was adjusted for age (continuous variable) and gender, model 3 was adjusted in addition to age and sex for coronary artery disease (none, stable CAD, unstable CAD, NSTEMI, STEMI), body mass index (continuous variable), diabetes mellitus (coded as binary variable), hypertension (coded as binary variable), smoking (coded as never, previous or current), HDL- and LDL-cholesterol, triglycerides (all used as continuous variables), lipid lowering therapy (coded as binary variable). Model 4 was additionally adjusted for hs CRP (continuous variable), and model 5 for creatinine.

Analyses were considered significant at a 2-tailed p-value of <0.05. All calculations were performed using SPSS Version 21.0.

Results

Associations of NGAL with cardiovascular risk factors and CAD

Clinical and biochemical characteristics of the study participants with and without angiographic established CAD are shown in S1 Table. Patients with CAD had higher cystatin C and creatinine levels and consequently a somewhat higher NGAL plasma level (not significant). As expected, patients with CAD were older, male, suffered from insulin resistance or manifest diabetes and hypertension and had a history of smoking. Consequently, dyslipidemia and vascular complications were more frequent than in individuals without CAD (S1 Table).

No differences in plasma NGAL levels were noted between male and females. However, NGAL levels increased age-dependently and were 8.7 and 12.4% higher in persons older than 60 and 70 years, respectively, as compared to those younger than 60 years (Table 1).

Patients with stable CAD had slightly higher NGAL concentrations than individuals without CAD, but those with unstable CAD, NSTEMI, or STEMI had slightly lower NGAL concentrations (not significant). Body mass index, waist circumference, diabetes mellitus and insulin resistance were inversely associated with NGAL concentrations (Table 1). When we looked at the NGAL levels in patients with and without CAD separately, the associations in individuals without CAD were abolished (S2 Table).

Smoking, dyslipidemia, uric acid, triglycerides, prevalence of peripheral vascular disease, blood pressure, use of antiplatelet and lipid lowering drugs, AT1 receptor antagonists as well as calcium channel blockers were not related to NGAL (data not shown). However, HDL cholesterol was associated with lower NGAL. In contrast to this, only the 4th quartile of LDL

NGAL and mortality in the LURIC cohort

PLOS ONE | DOI:10.1371/journal.pone.0171574 February 16, 2017 4 / 16
Table 1. Association of NGAL with cardiovascular risk factors and coronary artery disease.

|                                | n    | NGAL (ng/mL) | Difference (%) | \( P \)  |
|--------------------------------|------|--------------|----------------|--------|
| **Gender**                     |      |              |                |        |
| Men                            | 2069 | 40.3 (39.2–41.5) |                |        |
| Women                          | 927  | 40.0 (38.2–41.8) | -0.7           | 0.759  |
| **Age, years**                 |      |              |                |        |
| <60                            | 1098 | 37.8 (36.3–39.4) |                |        |
| 60–70                          | 1071 | 41.1 (39.5–42.7) | +8.7           | 0.005  |
| >70                            | 827  | 42.5 (40.5–44.5) | +12.4          | <0.001 |
| **Coronary artery disease**    |      |              |                |        |
| None                           | 638  | 40.0 (38.0–42.3) |                |        |
| Stable CAD                     | 1408 | 41.1 (39.8–42.6) | +2.8           | 0.415  |
| Unstable CAD (Troponin T-)     | 585  | 39.3 (37.2–41.4) | -1.8           | 0.606  |
| NSTEMI or STEMI (Troponin T+)  | 365  | 38.5 (35.9–41.2) | -3.8           | 0.393  |
| **Body mass index, kg/m\(^2\)**|      |              |                |        |
| ≤27 or 26\(^d\)               | 1407 | 41.9 (40.4–43.4) |                |        |
| >27 or 26\(^d\)               | 1589 | 38.8 (37.6–40.1) | -7.4           | 0.002  |
| **Waist circumference, cm**    |      |              |                |        |
| ≤102 or 88\(^b\)              | 1564 | 41.7 (40.3–43.1) |                |        |
| >102 or 88\(^b\)              | 1432 | 38.6 (37.3–40.0) | -7.4           | 0.003  |
| **Diabetes mellitus**          |      |              |                |        |
| No                             | 1810 | 41.5 (40.2–42.8) |                |        |
| Yes                            | 1186 | 38.3 (36.9–39.8) | -7.7           | 0.002  |
| **Insulin resistance by HOMA** |      |              |                |        |
| ≤2.5                           | 1703 | 41.2 (39.9–42.6) |                |        |
| >2.5                           | 1209 | 38.8 (37.3–40.3) | -5.8           | 0.023  |
| **Hypertension**               |      |              |                |        |
| No                             | 815  | 39.8 (38.0–41.7) |                |        |
| Yes                            | 2181 | 40.4 (39.3–41.5) | +1.5           | 0.631  |
| **Smoking**                    |      |              |                |        |
| Never                          | 1087 | 40.2 (38.6–41.9) |                |        |
| Former                         | 1341 | 40.2 (38.8–41.7) | 0              | 0.996  |
| Current                        | 568  | 40.2 (37.9–42.6) | 0              | 0.975  |
| **Lipid-lowering drugs**       |      |              |                |        |
| No                             | 1530 | 40.9 (39.5–42.3) |                |        |
| Yes                            | 1466 | 39.5 (38.2–40.9) | -3.4           | 0.184  |
| **LDL cholesterol, g/L**       |      |              |                |        |
| 1\(^st\) quartile (<0.95)     | 758  | 39.4 (37.6–41.3) |                |        |
| 2\(^nd\) quartile (0.95–1.14) | 746  | 39.7 (37.9–41.6) | +0.8           | 0.844  |
| 3\(^rd\) quartile (1.15–1.38) | 755  | 39.6 (37.8–41.5) | +0.5           | 0.886  |
| 4\(^th\) quartile (≥1.39)     | 737  | 42.3 (40.3–44.3) | +7.4           | 0.040  |
| **HDL cholesterol, g/L**       |      |              |                |        |
| 1\(^st\) quartile (<0.32)     | 761  | 43.5 (41.4–45.7) |                |        |
| 2\(^nd\) quartile (0.32–0.37) | 762  | 40.3 (38.5–42.2) | -7.4           | 0.023  |
| 3\(^rd\) quartile (0.38–0.44) | 692  | 38.5 (36.8–40.6) | -11.5          | 0.001  |
| 4\(^th\) quartile (≥0.45)     | 781  | 38.5 (36.7–40.4) | -11.5          | 0.001  |
| **Triglycerides, g/L**         |      |              |                |        |
| 1\(^st\) quartile (<1.09)     | 749  | 40.0 (38.1–42.1) |                |        |
| 2\(^nd\) quartile (1.09–1.46) | 746  | 40.5 (38.7–42.5) | +1.3           | 0.729  |

(Continued)
cholesterol was associated with a small, but significant NGAL increase (7.4% compared to the 1st quartile). CRP was positively associated with NGAL concentrations.

eGFR was inversely related to NGAL and vice versa; likewise, NGAL increased significantly in parallel with creatinine and cystatin C which was seen in patients with CAD and individuals without CAD (S2 Table). Finally, the 2nd quartile of the Friesinger score showed the highest concentration of NGAL (p = 0.022), whereas values were lower in the 3rd and 4th quartile.

Clinical and biochemical patient characteristics according to quartiles of NGAL

Patients in the 4th quartile of NGAL were at significantly higher age than the others, whereas no differences were noted with respect to sex (Table 2). Interestingly, the highest percentage of diabetes was noted in the first quartile of NGAL. Conversely, significant differences were seen for blood glucose, cholesterol, triglycerides, CRP, eGFR, creatinine, cystatin C (Table 2) as well as for the use of ACE inhibitors, diuretics, antibiotics, glucocorticoids (data not shown).
NGAL was available in 2997 persons (mean age: 62.7 ± 10.5 years; 30.3% women) with a follow-up for 10 years. Of those 2359 suffered from CAD and 638 did not. 900 patients died, 571 of those were due to cardiovascular causes (data not shown). CAD was clinically stable in 1408 and unstable (angina pectoris, NSTEMI, STEMI) in 951 patients, respectively.

All cause and cardiovascular mortality were highest in patients within the 4th quartile of NGAL (hazard ratio, (HR) 1.36 95%CI 1.13–1.63 and HR 1.39 95%CI 1.11–1.75), even after adjustment for age and gender (Tables 3 and 4).

Multivariable-adjusted Cox analysis additionally adjusting for cardiovascular risk factors, lipid lowering therapy, angiographic coronary artery disease, and C-reactive protein demonstrated patients in the highest NGAL quartile being at increased risk for cardiovascular (HR1.34, 95%CI 1.06–1.69) and all cause mortality (HR 1.30 (95%CI 1.08–1.56) compared to those in the third quartile. Since the lowest risk was seen in the third quartile of NGAL (3rd

### Table 2. Clinical and biochemical characteristics of study participants at baseline.

| NGAL, ng/mL | <30 (n = 728) | 30–40 (n = 765) | 41–56 (n = 775) | ≥56 (n = 729) | P² |
|-------------|---------------|----------------|----------------|--------------|----|
| Age, years  | 62±11         | 62±11          | 62±10          | 65±10        | <0.001 |
| Male sex    | 70            | 68             | 69             | 70           | 0.740² |
| Body mass index, kg/m² | 28±4 | 27±4 | 28±4 | 27±4 | 0.015 |
| Waist circumference, cm | 100±12 | 99±12 | 99±12 | 98±12 | 0.032 |
| Diabetes mellitus % | 47      | 36             | 35             | 41           | <0.001 |
| Insulin resistance by HOMA | 3.5±4.4 | 3.1±3.4 | 3.1±3.6 | 3.1±4.1 | 0.061 |
| Systemic hypertension % | 74      | 69             | 74             | 75           | 0.065 |
| Smoking %   | Never 36      | 36             | 37             | 36           |       |
| Past 44     | 46            | 45             | 44             |       |
| Current 20  | 18            | 18             | 19             |       |
| Previous myocardial infarction % | 42     | 38             | 40             | 45          | 0.023 |
| Peripheral vascular disease % | 9       | 9              | 9              | 11          | 0.599 |
| Cerебrovascular disease % | 9       | 7              | 9              | 11          | 0.049 |
| Systolic blood pressure, mmHg | 142±24 | 140±23 | 141±23 | 142±25 | 0.501³c |
| Diastolic blood pressure, mmHg | 81±11 | 81±11 | 81±11 | 80±12 | 0.107³c |
| Fasting blood glucose, g/L | 1.18±0.39 | 1.12±0.35 | 1.11±0.32 | 1.12±0.36 | <0.001 |
| LDL cholesterol, g/L | 1.13±0.33 | 1.16±0.33 | 1.20±0.36 | 1.17±0.35 | 0.001³d |
| HDL cholesterol, g/L | 0.38±0.11 | 0.40±0.10 | 0.40±0.11 | 0.38±0.11 | <0.001³e |
| Triglycerides, g/L | 1.54 (1.14–2.10) | 1.37 (1.04–1.90) | 1.46 (1.09–1.98) | 1.52 (1.13–2.02) | <0.001³e |
| C-reactive protein, mg/L | 3.6 (1.4–9.3) | 2.7 (1.1–6.8) | 3.0 (1.1–7.2) | 4.4 (1.7–10.7) | <0.001³e |
| eGFR, mL/min (CKD-EPI) | 88±17 | 87±17 | 82±16 | 69±23 | <0.001³e |
| Creatinine, mg/dL | 0.82±0.21 | 0.84±0.21 | 0.88±0.23 | 1.14±0.92 | <0.001³d |
| Cystatin C, mg/L | 0.90±0.20 | 0.90±0.19 | 0.96±0.23 | 1.24±0.69 | <0.001³d |

Values are mean ± SD, % or median (25th–75th percentile), respectively

²ANOVA or logistic regression, respectively, adjusted for age and gender

³Logistic regression, adjusted for age only

⁴Adjusted for use of beta blockers, ACE inhibitors, AT1 receptor antagonists, calcium channel blockers, diuretics and lipid-lowering drugs

⁵Adjusted for use of lipid-lowering drugs

⁶ANOVA of logarithmically transformed values

---

**NGAL and risk prediction in CAD**

NGAL was available in 2997 persons (mean age: 62.7±10.5 years; 30.3% women) with a follow-up for 10 years. Of those 2359 suffered from CAD and 638 did not. 900 patients died, 571 of those were due to cardiovascular causes (data not shown). CAD was clinically stable in 1408 and unstable (angina pectoris, NSTEMI, STEMI) in 951 patients, respectively.

All cause and cardiovascular mortality were highest in patients within the 4th quartile of NGAL (hazard ratio, (HR) 1.36 95%CI 1.13–1.63 and HR 1.39 95%CI 1.11–1.75), even after adjustment for age and gender (Tables 3 and 4).

Multivariable-adjusted Cox analysis additionally adjusting for cardiovascular risk factors, lipid lowering therapy, angiographic coronary artery disease, and C-reactive protein demonstrated patients in the highest NGAL quartile being at increased risk for cardiovascular (HR1.34, 95%CI 1.06–1.69) and all cause mortality (HR 1.30 (95%CI 1.08–1.56) compared to those in the third quartile. Since the lowest risk was seen in the third quartile of NGAL (3rd

doi:10.1371/journal.pone.0171574.t002
quartile), these data suggest an U-shaped relationship between NGAL and mortality which was true for all patients irrespective of whether they presented with stable CAD, unstable CAD, NSTEMI and STEMI (data not shown). Adjusting for creatinine abolished the significant associations of NGAL with mortality (model 5, Tables 3 and 4). We conducted a subgroup analysis according to an eGFR greater versus smaller (or equal) 60 ml/min/1.73m². All cause and cardiovascular mortality rates were considerably higher (60.3% vs. 25.1% and 42.0 vs.15.5%, respectively) in those patients with low compared to higher eGFR (>60 ml/min/1.73m²) (Tables 5 and 6).

Table 3. Hazard ratios (HR) for death from all causes according to NGAL.

| NGAL (ng/mL) | Deaths n (%) | Model 1 (HR (95% CI)) | P | Model 2 (HR (95% CI)) | P | Model 3 (HR (95% CI)) | P | Model 4 (HR (95% CI)) | P | Model 5 (HR (95% CI)) | P |
|-------------|--------------|-----------------------|---|----------------------|---|----------------------|---|----------------------|---|----------------------|---|
| All individuals (n = 2997) | | | | | | | | | | | |
| 1st quartile (<30) | 227 (31) | 1.29 (1.06–1.56) | 0.009 | 1.23 (1.01–1.49) | 0.036 | 1.12 (0.92–1.36) | 0.259 | 1.11 (0.92–1.35) | 0.286 | 1.14 (0.93–1.39) | 0.200 |
| 2nd quartile (30–40) | 195 (26) | 1.01 (0.83–1.23) | 0.936 | 1.00 (0.82–1.22) | 0.999 | 0.99 (0.81–1.21) | 0.935 | 0.99 (0.81–1.21) | 0.905 | 0.98 (0.80–1.21) | 0.863 |
| 3rd quartile (41–56) | 196 (25) | 1.0reference | 1.0reference | 1.0reference | 1.0reference | 1.0reference | 1.0reference | 1.0reference | 1.0reference | |
| 4th quartile (≥56) | 282 (39) | 1.68 (1.40–2.02) | <0.001 | 1.36 (1.13–1.63) | 0.001 | 1.30 (1.08–1.56) | 0.006 | 1.29 (1.07–1.55) | 0.007 | 1.18 (0.97–1.43) | 0.100 |

a Model 1: unadjusted  
b Model 2: adjusted for age and gender  
c Model 3: additionally adjusted for coronary artery disease (none, stable CAD, unstable CAD, NSTEMI, STEMI), body mass index, diabetes mellitus, hypertension, smoking status, LDL cholesterol, HDL cholesterol, triglycerides  
d Model 4: additionally adjusted for C-reactive protein  
e Model 5: additionally adjusted for creatinine

doi:10.1371/journal.pone.0171574.t003

Table 4. Hazard ratios (HR) for death from cardiovascular causes according to NGAL.

| NGAL (ng/mL) | Deaths n (%) | Model 1 (HR (95% CI)) | P | Model 2 (HR (95% CI)) | P | Model 3 (HR (95% CI)) | P | Model 4 (HR (95% CI)) | P | Model 5 (HR (95% CI)) | P |
|-------------|--------------|-----------------------|---|----------------------|---|----------------------|---|----------------------|---|----------------------|---|
| All individuals (n = 2978) | | | | | | | | | | | |
| 1st quartile (<30) | 141 (20) | 1.26 (0.99–1.61) | 0.059 | 1.20 (0.94–1.53) | 0.137 | 1.07 (0.84–1.37) | 0.585 | 1.06 (0.83–1.36) | 0.626 | 1.11 (0.86–1.43) | 0.437 |
| 2nd quartile (30–40) | 123 (16) | 1.01 (0.78–1.29) | 0.960 | 1.00 (0.78–1.28) | 0.980 | 0.99 (0.77–1.27) | 0.926 | 0.98 (0.77–1.26) | 0.896 | 1.00 (0.77–1.30) | 0.983 |
| 3rd quartile (41–56) | 124 (16) | 1.0reference | 1.0reference | 1.0reference | 1.0reference | 1.0reference | 1.0reference | 1.0reference | 1.0reference | |
| 4th quartile (≥56) | 183 (25) | 1.72 (1.37–2.16) | <0.001 | 1.39 (1.11–1.75) | 0.005 | 1.34 (1.06–1.69) | 0.013 | 1.33 (1.05–1.67) | 0.016 | 1.24 (0.97–1.58) | 0.091 |

a Model 1: unadjusted  
b Model 2: adjusted for age and gender  
c Model 3: additionally adjusted for coronary artery disease (none, stable CAD, unstable CAD, NSTEMI, STEMI), body mass index, diabetes mellitus, hypertension, smoking status, LDL cholesterol, HDL cholesterol, triglycerides  
d Model 4: additionally adjusted for C-reactive protein  
e Model 5: additionally adjusted for creatinine

doi:10.1371/journal.pone.0171574.t004
Among patients with an eGFR > 60 ml/min/1.73 m² the highest number of deaths from all causes occurred in the first quartile even after adjustment for creatinine (HR 1.17 95%CI 0.94–1.47) for cardiovascular deaths a consistent trend was noted HR 1.24 95%CI 0.93–1.65). In the 418 patients with impaired renal function (eGFR ≤60 ml/min/1.73 m²) no significant effects were seen (Tables 7 and 8). When we plotted eGFR, hsCRP and NGAL in a three-dimensional graph we found a rather weak association of CRP with NGAL in the eGFR range of 60–90 ml/min/1.73 m², but not in those subjects with good (higher than 90 ml/min/1.73 m²) and reduced (less than sixty ml/min/1.73 m²) kidney function (S1 Fig).

As expected we found a significant association between NGAL and the absolute and relative neutrophil count (p<0.001, data not shown). The 3rd and 4th quartiles of NGAL were significantly associated with both, higher neutrophil count and higher percentage of neutrophils.

### Table 5. Hazard ratios (HR) for death from all causes according to NGAL (eGFR > 60 ml/min/1.73 m²).

| NGAL (ng/mL) | Deaths | Model 1 | P | Model 2 | P | Model 3 | P | Model 4 | P | Model 5 | P |
|--------------|--------|---------|---|---------|---|---------|---|---------|---|---------|---|
| n (%) | HR (95% CI) | | | HR (95% CI) | | | HR (95% CI) | | | HR (95% CI) | |
| All individuals (n = 2576) | | | | | | | | | | | |
| 1st quartile (<30) | 200 (29) | 1.44 (1.17–1.79) | 0.001 | 1.35 (1.09–1.67) | 0.006 | 1.23 (0.99–1.52) | 0.061 | 1.22 (0.98–1.51) | 0.073 | 1.17 (0.94–1.47) | 0.166 |
| 2nd quartile (30–40) | 166 (23) | 1.10 (0.88–1.37) | 0.396 | 1.11 (0.89–1.38) | 0.379 | 1.10 (0.88–1.37) | 0.420 | 1.09 (0.88–1.37) | 0.430 | 1.05 (0.83–1.32) | 0.705 |
| 3rd quartile (41–56) | 148 (21) | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| 4th quartile (≥56) | 133 (28) | 1.34 (1.06–1.70) | 0.013 | 1.22 (0.97–1.55) | 0.094 | 1.19 (0.94–1.51) | 0.141 | 1.18 (0.94–1.50) | 0.162 | 1.10 (0.86–1.41) | 0.459 |

**a** Model 1: unadjusted  
**b** Model 2: adjusted for age and gender  
**c** Model 3: additionally adjusted for coronary artery disease (none, stable CAD, unstable CAD, NSTEMI, STEMI), body mass index, diabetes mellitus, hypertension, smoking status, LDL cholesterol, HDL cholesterol, triglycerides  
**d** Model 4: additionally adjusted for C-reactive protein  
**e** Model 5: additionally adjusted for creatinine

### Table 6. Hazard ratios (HR) for death from cardiovascular causes according to NGAL (eGFR > 60 ml/min/1.73 m²).

| NGAL (ng/mL) | Deaths | Model 1 | P | Model 2 | P | Model 3 | P | Model 4 | P | Model 5 | P |
|--------------|--------|---------|---|---------|---|---------|---|---------|---|---------|---|
| n (%) | HR (95% CI) | | | HR (95% CI) | | | HR (95% CI) | | | HR (95% CI) | |
| All individuals (n = 2561) | | | | | | | | | | | |
| 1st quartile (<30) | 128 (19) | 1.53 (1.17–2.01) | 0.002 | 1.43 (1.09–1.88) | 0.009 | 1.28 (0.97–1.68) | 0.080 | 1.26 (0.96–1.66) | 0.097 | 1.24 (0.93–1.65) | 0.148 |
| 2nd quartile (30–40) | 105 (15) | 1.16 (0.87–1.54) | 0.308 | 1.16 (0.88–1.54) | 0.296 | 1.15 (0.86–1.52) | 0.349 | 1.14 (0.86–1.52) | 0.360 | 1.11 (0.83–1.49) | 0.488 |
| 3rd quartile (41–56) | 89 (13) | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| 4th quartile (≥56) | 75 (16) | 1.26 (0.92–1.71) | 0.145 | 1.14 (0.84–1.55) | 0.397 | 1.13 (0.83–1.54) | 0.425 | 1.12 (0.82–1.53) | 0.470 | 1.04 (0.75–1.44) | 0.816 |

**a** Model 1: unadjusted  
**b** Model 2: adjusted for age and gender  
**c** Model 3: additionally adjusted for coronary artery disease (none, stable CAD, unstable CAD, NSTEMI, STEMI), body mass index, diabetes mellitus, hypertension, smoking status, LDL cholesterol, HDL cholesterol, triglycerides  
**d** Model 4: additionally adjusted for C-reactive protein  
**e** Model 5: additionally adjusted for creatinine

doi:10.1371/journal.pone.0171574.t005
doi:10.1371/journal.pone.0171574.t006
Neutrophil counts were associated with CAD, non ST elevation and ST elevation myocardial infarction (NSTEMI and STEMI, \( p < 0.05 \), data not shown).

**Discussion**

In this study we investigated prospectively associations of plasma NGAL with all-cause and cardiovascular mortality in the LURIC cohort which represents an extremely well characterized population without overt kidney disease [20]. Even mildly impaired glomerular filtration, estimated by serum creatinine or serum cystatin C, or albuminuria predict cardiovascular and all-cause mortality. Consequently, chronic renal impairment is now considered a significant cardiovascular risk factor [27–29].

Table 7. Hazard ratios (HR) for death from all causes according to NGAL (eGFR ≤60 ml/min/1.73 m²).

| NGAL (ng/mL) | Deaths | Model 1 | | | Model 2 | | | Model 3 | | | Model 4 | | | Model 5 | | |
|--------------|--------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
|              | n (%)  | HR (95% CI)a | P | HR (95% CI)b | P | HR (95% CI)c | P | HR (95% CI)d | P | HR (95% CI)e | P |
| All individuals (\( n = 418 \)) | | | | | | | | | | | | | | |
| 1\textsuperscript{st} quartile (<30) | 26 (63) | 1.24 (0.77–2.00) | 0.372 | 1.15 (0.71–1.87) | 0.558 | 1.06 (0.65–1.73) | 0.815 | 1.06 (0.65–1.73) | 0.815 | 1.24 (0.75–2.06) | 0.404 |
| 2\textsuperscript{nd} quartile (30–40) | 29 (58) | 0.99 (0.62–1.57) | 0.961 | 0.88 (0.56–1.41) | 0.601 | 0.87 (0.54–1.38) | 0.546 | 0.87 (0.54–1.38) | 0.546 | 1.01 (0.62–1.64) | 0.963 |
| 3\textsuperscript{rd} quartile (41–56) | 48 (59) | 1.0 reference | 1.0 reference | 1.0 reference | 1.0 reference | 1.0 reference | 1.0 reference | 1.0 reference | 1.0 reference | 1.0 reference | 1.0 reference |
| 4\textsuperscript{th} quartile (56) | 149 (61) | 1.06 (0.76–1.46) | 0.743 | 0.99 (0.72–1.38) | 0.963 | 0.94 (0.68–1.31) | 0.732 | 0.94 (0.68–1.31) | 0.732 | 0.94 (0.66–1.33) | 0.717 |

a Model 1: unadjusted
b Model 2: adjusted for age and gender
c Model 3: additionally adjusted for coronary artery disease (none, stable CAD, unstable CAD, NSTEMI, STEMI), body mass index, diabetes mellitus, hypertension, smoking status, LDL cholesterol, HDL cholesterol, triglycerides
d Model 4: additionally adjusted for C-reactive protein
e Model 5: additionally adjusted for creatinine

doi:10.1371/journal.pone.0171574.t007

Table 8. Hazard ratios (HR) for death from cardiovascular causes according to NGAL (eGFR ≤60 ml/min/1.73 m²).

| NGAL (ng/mL) | Deaths | Model 1 | | | Model 2 | | | Model 3 | | | Model 4 | | | Model 5 | | |
|--------------|--------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
|              | n (%)  | HR (95% CI)a | P | HR (95% CI)b | P | HR (95% CI)c | P | HR (95% CI)d | P | HR (95% CI)e | P |
| All individuals (\( n = 414 \)) | | | | | | | | | | | | | | |
| 1\textsuperscript{st} quartile (<30) | 13 (33) | 0.85 (0.45–1.61) | 0.624 | 0.80 (0.42–1.52) | 0.499 | 0.70 (0.37–1.33) | 0.277 | 0.70 (0.36–1.33) | 0.277 | 0.80 (0.40–1.59) | 0.525 |
| 2\textsuperscript{nd} quartile (30–40) | 18 (36) | 0.85 (0.48–1.49) | 0.561 | 0.77 (0.43–1.36) | 0.364 | 0.75 (0.42–1.33) | 0.320 | 0.75 (0.42–1.34) | 0.328 | 0.93 (0.51–1.70) | 0.819 |
| 3\textsuperscript{rd} quartile (41–56) | 35 (43) | 1.0 reference | 1.0 reference | 1.0 reference | 1.0 reference | 1.0 reference | 1.0 reference | 1.0 reference | 1.0 reference |
| 4\textsuperscript{th} quartile (56) | 108 (44) | 1.06 (0.72–1.55) | 0.764 | 1.01 (0.69–1.48) | 0.980 | 0.95 (0.65–1.41) | 0.811 | 0.96 (0.65–1.41) | 0.816 | 1.01 (0.66–1.53) | 0.978 |

a Model 1: unadjusted
b Model 2: adjusted for age and gender
c Model 3: additionally adjusted for coronary artery disease (none, stable CAD, unstable CAD, NSTEMI, STEMI), body mass index, diabetes mellitus, hypertension, smoking status, LDL cholesterol, HDL cholesterol, triglycerides
d Model 4: additionally adjusted for C-reactive protein
e Model 5: additionally adjusted for creatinine

doi:10.1371/journal.pone.0171574.t008
Our most important finding is that NGAL was independently associated with all-cause and CVD mortality. The lowest risk was seen in the third quartile of NGAL suggesting an U-shaped relationship between NGAL and mortality. Compared to conventional cardiovascular risk factors, NGAL was predictive even after adjustment for hsCRP. However, this effect was abrogated after adjustment for creatinine and eGFR. We found an inverse and highly significant nonlinear correlation of NGAL with creatinine, cystatin C and eGFR. Although eGFR appeared to associate closer with NGAL when eGFR was lower than 60mL/min/1.73m² we could not prove a significant role of NGAL in patients with either reduced or normal eGFR.

Similar to our results patients with CHF secondary to CAD, but with normal renal function presented with markedly elevated plasma NGAL levels compared to individuals without CAD. Importantly, the increase in NGAL independently correlated with both the NYHA stage and the estimated GFR [30]. In our study NGAL levels were associated with diabetes and insulin resistance which is supported by other investigators [31].

As indicated by its strong correlation with each other the major amount of NGAL may be derived from neutrophils. This hypothesis is underlined by a community-based study from Copenhagen that also attributed plasma NGAL being primarily derived from neutrophils [19]. Since the main determinant of plasma NGAL are neutrophils, but monocyte-, hepatocyte-, endothelial-, smooth muscle cell-, renal tubular cells contribute also to NGAL levels the predictive role of systemic NGAL may be attenuated [2, 3].

Unfortunately, we had no urine specimens available to examine urinary NGAL. Although NGAL was significantly associated with hsCRP it provided predictive information even after inclusion of hsCRP into the regression model; NGAL may thus reflect vascular inflammation beyond CRP. Likewise, we found statistically significant associations between NGAL and cardiovascular risk factors, similar to other investigators [15, 19].

Published studies of NGAL are not entirely consistent with our results: In a Swedish study of 597 men, plasma NGAL was associated with all-cause mortality independent of other cardiovascular risk factors, but not after adjustment for CRP, cystatin C-based eGFR or albuminuria. In this study, however, urine NGAL was associated with increased all-cause and cardiovascular mortality even after adjustments for CRP and cystatin C-based glomerular filtration rate [32].

Among patients with chronic kidney disease, urine NGAL was independently associated with future ischemic atherosclerotic events, but not with heart failure events or deaths [33].

Furthermore, atherosclerosis is mediated by matrix metalloproteinases (MMPs), which are counteracted by tissue inhibitors of MMP (TIMPs) and NGAL [8, 9]. NGAL has been identified in the cytosol and in a complex containing matrix metalloproteinase-9 (MMP-9). Experimentally, vascular injury was followed by NF-kappaB-dependent expression of NGAL in vascular smooth muscle cells. NGAL obviously interacted with MMP-9, so that NGAL could modulate MMP-9 proteolytic activity in the vascular repair process [9]. Very recently it has been demonstrated that aldosterone induces MMP-9 and MMP-9/NGAL protein complex in neutrophils [13]. In general, the action of MMPs is inhibited when combined with tissue inhibitors of MMPs (TIMPs), and prolonged when these proteases bind to NGAL [34]. However, experimental data are conflicting: A significant increase in MMP9/TIMP2 complex concentration was noted in intraluminal thrombi of patients on simvastatin, but no changes in the expression of NGAL mRNA or the protein concentration of MMP9/NGAL whereas gene expression of TIMP1 in the aneurysma wall was downregulated [35]. Thus, an important role of NGAL modulating inflammation and atherosclerosis is conceivable. This is underlined by a couple of publications that attributed either a predictive role to NGAL with respect to morbidity or mortality or could show NGAL expression in atherosclerotic tissue plaques and myocardial infarction [10, 15, 19, 36–42]. It is noteworthy, that lipid lowering therapy by statins
stimulates the shedding of the soluble type I transmembrane protein receptor for advanced glycation end products (RAGE), and thus ameliorates atherosclerosis via acting as a decoy for RAGE ligands [43].

Of note is that our NGAL concentrations are considerably lower than those published by investigators who proposed a stronger predictive role for NGAL. However, these differences may be ascribed to different assay characteristics. Lindberg used an in-house time resolved immunofluorometric assay in the 4th Copenhagen City Heart Study, whereas we measured NGAL by using a particle-enhanced turbidimetric immunoassay [15, 19]. Nonetheless, we ought to keep in mind that the absence of an appropriate reference material to be used to calibrate the applied assays, lack of harmonization and differences in the specificity of these assays could explain the observed differences between the studies.

Study limitations
Timing of blood samples is an issue in the studies investigating NGAL and CAD. We measured NGAL before the invasive procedure to control for influences of contrast media and increase in NGAL due to direct damage of the kidney like ischemia-reperfusion injury possibly caused by the angiography maneuver [44, 45]. Blood drawings for determination of NGAL and other markers took place once at study entry. Therefore, it is conceivable that additional blood sampling would have provided a more accurate correlation with other inflammatory markers or would have enhanced the predictive value [46]. Furthermore, besides albuminuria also urinary NGAL compared with plasma NGAL levels would have been useful to characterize its predictive value.

Since we cannot rely on a gold-standard GFR measurement we should note that even mild reductions in kidney function, putatively not reflected by creatinine or cystatin C, could modify myocardial function and consequently increase the risk for sudden cardiac death, without any clinical evidence of CHF, coronary disease, or structural changes of the myocardium. Furthermore, our study was conducted at a single tertiary referral center and may not be representative for a random population sample. Consequently, a larger number of individuals without CAD would be desirable in the LURIC cohort. However, one of the inclusion criteria of the LURIC study was the availability of a coronary angiogram and recruitment was consecutive. Since coronary angiography is done if there is a clinical suspicion of coronary artery disease, there has been an enrichment of male cases compared to females. However, angiography-based recruitment of study participants rules out that individuals with significant, yet clinically unapparent, CAD are inadvertently allocated to the control group. Further, angiographic findings represent a continuum of changes starting from wall irregularities to severe occlusion so that we used quantitative measures of coronary atherosclerosis like the Friesinger score. We are aware that optical in vivo assessment of the coronary wall with high resolution optical coherence tomography (OCT) offers a number of specific diagnostic features to study culprit lesions in patients with different clinical presentations (e.g. NSTEMI, or STEMI) and give insight into the dynamic nature of atherosclerotic plaque formation, modification and rupture. However, unfortunately, OCT analyses are not available in the LURIC cohort, since the baseline examination took place between 1997 and 2001 and the severity of CAD was assessed using coronary angiography [47, 48]. Furthermore, we have no records on non-fatal myocardial infarction or other non-fatal endpoints as the LURIC study was designed to identify biomarkers for cardiovascular and total mortality.

Because the LURIC cohort consists mainly of elderly persons, the described associations of NGAL with mortality cannot necessarily be extrapolated to younger populations even after adjusting for age. Finally, as with any observational study, there may be residual confounding
of the association of NGAL with CAD, CV diseases and all-cause mortality irrespective of statistical adjustments.

**Conclusions**

In the LURIC cohort plasma NGAL is independently associated with all-cause and CVD mortality even after controlling for conventional cardiovascular risk factors including hsCRP but adjustment for creatinine abrogates this effect.

**Supporting information**

**S1 Fig. Association of eGFR, hsCRP and NGAL.** A three-dimensional graph depicting the association between percentiles of hsCRP with NGAL and eGFR in which eGFR is clustered in $\leq 60$ ml/min/1.73m$^2$, 60–90 ml/min/1.73m$^2$, and $> 90$ ml/min/1.73m$^2$.

(PDF)

**S1 Table. Clinical and biochemical characteristics of study participants at baseline in individuals with and without CAD.** Values are mean ± SD or median (25th and 75th percentile), respectively. a ANOVA or logistic regression, respectively, adjusted for age and gender. b Logistic regression, adjusted for age only. c Adjusted for use of beta blockers, ACE inhibitors, AT1 receptor antagonists, calcium channel blockers, diuretics and lipid-lowering agents. d Adjusted for use of lipid-lowering agents. e ANOVA of logarithmically transformed values.

(PDF)

**S2 Table. Association of NGAL with cardiovascular risk factors and coronary artery disease in individuals with and without CAD.** a Estimated marginal means and 95% confidence intervals obtained in a general linear model (ANOVA), adjusted for sex, gender, coronary artery disease, body mass index, diabetes mellitus, hypertension, smoking, LDL cholesterol, HDL cholesterol, triglycerides. b Compared to the first category of each variable. c Post hoc pairwise comparisons with the first category of each variable. d Thresholds of 27 and 26 kg apply to males and females, respectively. e Thresholds of 102 and 88 cm apply to males and females, respectively.

(PDF)

**Acknowledgments**

We thank the LURIC team involved in patient recruitment, sample and data handling, and the laboratory staffs at the Ludwigshafen General Hospital, the Universities of Freiburg, Ulm, and Graz.

**Author Contributions**

**Conceptualization:** RW TS HS WM.

Data curation: MK.

Formal analysis: RW HS TS WM.

Funding acquisition: WM.

Investigation: HS TS.

Methodology: HS TS.

Project administration: WM.
Resources: WM HS TS.
Software: MK GD.
Supervision: WM.
Validation: TG WM TS HS.
Visualization: RW TS HS WM.
Writing – original draft: RW.
Writing – review & editing: RW TS WM BK MP.

References
1. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. The Journal of biological chemistry. 1993; 268 (14):10425–32. PMID: 7693678
2. Bolignano D, Coppolino G, Lacquaniti A, Buemi M. From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology. European journal of clinical investigation. 2010; 40 (3):273–6. doi: 10.1111/j.1365-2362.2010.02258.x PMID: 20415702
3. Folkesson M, Kazi M, Zhu C, Silveira A, Hemdahl AL, Hamsten A, et al. Presence of NGAL/MMP-9 complexes in human abdominal aortic aneurysms. Thrombosis and haemostasis. 2007; 98(2):427–33. PMID: 17721627
4. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005; 365 (9468):1231–8. doi: 10.1016/S0140-6736(05)74811-X PMID: 15811456
5. Goetz DH, Willie ST, Arsen RS, Bratt T, Borregaard N, Strong RK. Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. Biochemistry. 2000; 39(8):1935–41. PMID: 10684642
6. Kjeldsen L, Sengelov H, Lollike K, Nielsen MH, Borregaard N. Isolation and characterization of gelatinate granules from human neutrophils. Blood. 1994; 83(6):1640–9. PMID: 8123855
7. Bratt T, Ohlson S, Borregaard N. Interactions between neutrophil gelatinase-associated lipocalin and natural lipophilic ligands. Biochimica et biophysica acta. 1999; 1472(1–2):262–9. PMID: 10572948
8. Cowland JB, Sorensen OE, Sehested M, Borregaard N. Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1 beta, but not by TNF-alpha. Journal of immunology. 2003; 171(12):6630–9.
9. Bu DX, Hemdahl AL, Gabrielsen A, Fuxe J, Zhu C, Eriksson P, et al. Induction of neutrophil gelatinase-associated lipocalin in vascular injury via activation of nuclear factor-kappaB. The American journal of pathology. 2006; 169(6):2245–53. PubMed Central PMCID: PMC1762469. doi: 10.2353/ajpath.2006.050706 PMID: 17148685
10. Hemdahl AL, Gabrielsen A, Zhu C, Eriksson P, Hedin U, Kastrup J, et al. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arteriosclerosis, thrombosis, and vascular biology. 2006; 26(1):136–42. doi: 10.1161/01.ATV.0000193567.86885.f4 PMID: 16254208
11. Zografos T, Haliassos A, Korovesis S, Giazitzoglou E, Voridis E, Katritsis D. Association of neutrophil gelatinase-associated lipocalin with the severity of coronary artery disease. The American journal of cardiology. 2009; 104(7):917–20. doi: 10.1016/j.amjcard.2009.05.023 PMID: 1976756
12. Leclercq A, Houard X, Philippe M, Ollivier V, Sebag U, Meilhac O, et al. Involvement of intraplaque hemorrhage in atherothrombosis evolution via neutrophil protease enrichment. Journal of leukocyte biology. 2007; 82(6):1420–9. doi: 10.1189/jlb.1106671 PMID: 17827339
13. Gilet A, Zou F, Boumenir M, Fripiat JP, Thornton SN, Lacolley P, et al. Aldosterone up-regulates MMP-9 and MMP-9/NGAL expression in human neutrophils through p38, ERK1/2 and PI3K pathways. Experimental cell research. 2015; 331(1):152–63. doi: 10.1016/j.yexcr.2014.11.004 PMID: 25449897
14. Paulsson J, Dadfar E, Held C, Jacobson SH, Lundahl J. Activation of peripheral and in vivo transmigrated neutrophils in patients with stable coronary artery disease. Atherosclerosis. 2007; 192(2):329–34. doi: 10.1016/j.atherosclerosis.2006.08.003 PMID: 16963051
15. Lindberg S, Pedersen SH, Mogelvang R, Jensen JS, Flyvbjerg A, Galatius S, et al. Prognostic utility of neutrophil gelatinase-associated lipocalin in predicting mortality and cardiovascular events in patients
with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Journal of the American College of Cardiology. 2012; 60(4):339–45. Epub 2012/07/21. doi: 10.1016/j.jacc.2012.04.017 PMID: 22813613

16. Ronco C. Kidney attack: overdiagnosis of acute kidney injury or comprehensive definition of acute kidney syndromes? Blood purification. 2013; 36(2):65–8. doi: 10.1159/000354768 PMID: 23969548

17. Ronco C, Chawla LS. Acute kidney injury: Kidney attack must be prevented. Nature reviews Nephrology. 2013; 9(4):198–9. doi: 10.1038/nrneph.2013.19 PMID: 23399576

18. Soylu K, Aksan G, Nar G, Ozdemir M, Gulel O, Inci S, et al. Serum neutrophil gelatinase-associated lipocalin levels are correlated with the complexity and the severity of atherosclerosis in acute coronary syndrome. Andolu kardiyoloji dergisi: AKD = the Anatolian journal of cardiology. 2014.

19. Lindberg S, Jensen JS, Mogelvang R, Pedersen SH, Flyvbjerg A, et al. Plasma neutrophil gelatinase-associated lipocalin in the general population: association with inflammation and prognosis. Arteriosclerosis, thrombosis, and vascular biology. 2014; 34(9):2135–42. doi: 10.1161/ATVBAHA.114.303950 PMID: 24969771

20. Winkelmann BR, Marz W, Boehm BO, Zott R, Hager J, Hellstern P, et al. Rationale and design of the LURIC study—a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics. 2001; 2(1 Suppl 1):S1–73. Epub 2001/03/22.

21. Woitas RP, Kleber ME, Meinitzer A, Grammer TB, Silbernagel G, Pilz S, et al. Cystatin C is independently associated with total and cardiovascular mortality in individuals undergoing coronary angiography. The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Atherosclerosis. 2013; 229(2):541–8. doi: 10.1016/j.atherosclerosis.2013.04.027 PMID: 23706287

22. Stone NJ, Bilek S, Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. The American journal of cardiology. 2005; 96(4A):53E–9E. Epub 2005/08/16. doi: 10.1016/j.amjcard.2005.06.006 PMID: 16098845

23. Diagnosis and classification of diabetes mellitus. Diabetes care. 2012; 35 Suppl 1:S64–71. Epub 2012/01/04.

24. Curnow SJ, Fairclough M, Schmutz C, Kissane S, Denniston AK, Nash K, et al. Distinct types of fibrocyte can differentiate from mononuclear cells in the presence and absence of serum. PLoS one. 2010; 5(3):e9730. PubMed Central PMCID: PMC2841180. doi: 10.1371/journal.pone.0009730 PMID: 20305780

25. Carling RS, Hogg SL, Wood TC, Calvin J. Simultaneous determination of guanidinoacetate, creatine and creatinine in urine and plasma by un-derivatized liquid chromatography-tandem mass spectrometry. Ann Clin Biochem. 2008; 45:575–84. doi: 10.1258/acb.2008.008029 PMID: 18782816

26. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Annals of internal medicine. 2009; 150(9):604–12. Epub 2009/05/06.

27. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Annals of internal medicine. 2001; 134(8):629–36. PMID: 11304102

28. Mann JF, Gerstein HC, Pogue J, Lonn E, Yusuf S. Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors. American journal of cardiovascular drugs: drugs, devices, and other interventions. 2002; 2(3):157–62. PMID: 14727978

29. van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney international. 2011; 79(12):1341–52. doi: 10.1038/ki.2010.536 PMID: 21307840

30. Poniatowski B, Malyszko J, Bucharzewska-Gajewska H, Malyszko JS, Dobrzycki S. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in patients with chronic heart failure and coronary artery disease. Kidney & blood pressure research. 2009; 32(2):77–80.

31. Mahfouz MH, Assiri AM, Mukhtar MH. Assessment of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Retinol-Binding Protein 4 (RBP4) in Type 2 Diabetic Patients with Nephropathy. Biomark Insights. 2016; 11:31–40. PubMed Central PMCID: PMC4756860. doi: 10.4137/BMI.S33191 PMID: 26917947

32. Helmersson-Karlqvist J, Larsson A, Carlsson AC, Venge P, Sundstrom J, Ingelsson E, et al. Urine neutrophil gelatinase-associated lipocalin (NGAL) is associated with mortality in a community-based cohort of older Swedish men. Atherosclerosis. 2013. Epub 2013/02/06.

33. Liu KD, Yang W, Go AS, Anderson AH, Feldman HJ, Fischer MJ, et al. Urine Neutrophil Gelatinase-Associated Lipocalin and Risk of Cardiovascular Disease and Death in CKD: Results From the Chronic Renal Insufficiency Cohort (CRIC) Study. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2015; 65(2):267–74.
34. Folkesson M, Kazi M, Zh C, Silveira A, Hemclahl AL, Harristen A, et al. Presence of NGAL/MMP-9 complexes in human abdominal aortic aneurysms. Thromb Haemostasis. 2007; 98(2):427–33.

35. Piechota-Polanczyk A, Demynetans S, Mittboeck M, Hofmann M, Domenig CM, Neumayer C, et al. The Influence of Simvastatin on NGAL, Matrix Metalloproteinases and Their Tissue Inhibitors in Human Intraluminal Thrombus and Abdominal Aortic Aneurysm Tissue. Eur J Vasc Endovasc. 2015; 49 (5):549–55.

36. Akcay AB, Ozu MF, Sen N, Cay S, Ozturk OH, Yalc M, et al. Prognostic significance of neutrophil gelatinase-associated lipocalin in ST-segment elevation myocardial infarction. Journal of investigative medicine: the official publication of the American Federation for Clinical Research. 2012; 60(2):508–13. Epub 2012/01/10.

37. Bolignano D, Basile G, Parisi P, Coppolino G, Nicocia G, Buemi M. Increased plasma neutrophil gelatinase-associated lipocalin levels predict mortality in elderly patients with chronic heart failure. Rejuvenation research. 2009; 12(1):7–14. Epub 2009/02/07. doi: 10.1089/rej.2008.0803 PMID: 19196011

38. Daniels LB, Barrett-Connor E, Clopton P, Laughlin GA, Maisel AS. Plasma neutrophil gelatinase-associated lipocalin is independently associated with cardiovascular disease and mortality in community-dwelling older adults: The Rancho Bernardo Study. Journal of the American College of Cardiology. 2012; 59(12):1101–9. Epub 2012/03/17. PubMed Central PMCID: PMC3312791. doi: 10.1016/j.jacc.2011.11.046 PMID: 22421304

39. Furfuy F, Shimura H, Yokomichi H, Takahashi K, Asakawa C, et al. Neutrophil gelatinase-associated lipocalin levels associated with cardiovascular disease in chronic kidney disease patients. Clinical and experimental nephrology. 2014; 18(5):778–83. doi: 10.1007/s10157-013-0923-4 PMID: 24337622

40. Maisel AS, Mueller C, Fitzgerald R, Blikhan R, Hiestand BC, Iqbal N, et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL Evaluation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. European journal of heart failure. 2011; 13(8):846–51. Epub 2011/07/28. PubMed Central PMCID: PMC3143832. doi: 10.1093/eurjhf/hfr087 PMID: 21791540

41. Nymo SH, Uleland T, Askevold ET, Flo TH, Kjekshus J, Hulthe J, et al. The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: results from CORONA*. Journal of internal medicine. 2012; 271(5):436–43. Epub 2012/01/04. doi: 10.1111/j.1365-2796.2011.02503.x PMID: 22211640

42. Shavit L, Dolgoker I, Ivgi H, Assous M, Slotki I. Neutrophil gelatinase-associated lipocalin as a predictor of complications and mortality in patients undergoing non-cardiac major surgery. Kidney & blood pressure research. 2011; 34(2):116–24. Epub 2011/02/12.

43. Quade-Lysy P, Kanarek AM, Baisersdorfer M, Postina R, Kojro E. Statins stimulate the production of a soluble form of the receptor for advanced glycation end products. J Lipid Res. 2013; 54(11):3052–61. doi: 10.1194/jlr.M038968 PMID: 23966666

44. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Dobrzycki S. Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. American journal of nephrology. 2006; 26(3):287–92. doi: 10.1159/000093961 PMID: 16772710

45. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Dobrzycki S. Neutrophil gelatinase-associated lipocalin (NGAL) correlations with cystatin C, serum creatinine and eGFR in patients with normal serum creatinine undergoing coronary angiography. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association—European Renal Association. 2007; 22(1):295–6.

46. Choi KM, Lee JS, Kim EJ, Baik SH, Seo HS, Choi DS, et al. Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. European journal of endocrinology / European Federation of Endocrine Societies. 2008; 158(2):203–7.

47. Iannaccone M QG, Taha S, D’Ascenzo F, Montefusco A, Omide’ P, Jang IK, Niccoli G, Souteyrand G, Yundai C, Toutouzas K, Benedetto S, Barbero U, Annone U, Lonni E, Imori Y, Blondi-Zoccari G, Templin C, Moretti C, Luscher TF, Gaita F. Prevalence and predictors of culprit plaque rupture at OCT in patients with coronary artery disease: a meta-analysis. Eur Heart J Cardiovasc Imaging. 2016; 17(10):1128–37. doi: 10.1093/ehjci/jev283 PMID: 26508517

48. Kubo T, Tanaka A, Ino Y, Kitabata H, Shiono Y, Akasaka T. Assessment of Coronary Atherosclerosis using Optical Coherence Tomography. J Atheroscler Thromb. 2014; 21(9):895–903. PMID: 25069815